This presentation has been prepared by ANGLE plc (the "Company"). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the "Materials") are personal to the recipient and have been prepared and issued by or on behalf of the Company. The Materials have been prepared solely for use at a presentation to relevant persons (as defined below) in connection with the proposed placing (the "Placing") of ordinary shares in the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to the Placing upon the Company's request.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company's nominated adviser, finnCap ("finnCap") has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA") and accordingly it is a communication made only to persons who (a) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive it and (b) are an "eligible counterparty" within the meaning of Article 24(2), (3) and (4) of Directive 2004/39/EC ("MiFID") as implemented into national law of the relevant EEA state (together, the "Relevant Persons"). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to finnCap immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA). This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company's financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as "anticipates", "expects", "should", "intends", "plans", "believes", "outlook", "seeks", "estimates", "targets", "may", "will", "continue", "project" and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company's future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Company's and its subsidiaries (the "Group") research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group's products by customers.

The Materials may contain, and the fact of the proposed Placing constitutes, unpublished price sensitive information or inside information with regard to the Company and/or its securities. Recipients of the presentation should not deal or encourage any other person to deal in the securities of the Company whilst they remain in possession of such unpublished price sensitive information or inside information. Dealing in securities of the Company when in possession of unpublished price sensitive information or inside information could result in liability under the insider dealing restrictions set out in the Criminal Justice Act 1993 and/or the Market Abuse Regulation No. 596/2014 (MAR).

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors' Report section including the "Principal risks and uncertainties" in the most recent Annual Report & Accounts of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.
Highlights

- FDA clinical study set up and in progress

- **Large scale clinical studies in ovarian cancer out-perform standard of care**

- Acquisition of downstream analysis technology enables ‘sample to answer’

- **Collaborative agreements with QIAGEN, Philips and Abbott**

- Installed base increased to 200 Parsortix™ systems and over 49,000 blood separations completed

- **Growing body of published evidence of performance** from 17 separate cancer centres
### Financial Results for the year ended 30 April 2018 (unaudited)

<table>
<thead>
<tr>
<th>Statement of Comprehensive Income</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue and grant income</td>
<td>£680</td>
<td>£498</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(169)</td>
<td>(123)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>511</td>
<td>375</td>
</tr>
<tr>
<td>Operating costs</td>
<td>(9,444)</td>
<td>(7,810)</td>
</tr>
<tr>
<td>Tax credit and other income</td>
<td>1,395</td>
<td>1,043</td>
</tr>
<tr>
<td>Loss for the year</td>
<td>(7,538)</td>
<td>(6,392)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Statement of Financial Position</th>
<th>30Apr18</th>
<th>30Apr17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade and other receivables and R&amp;D tax credit</td>
<td>2,975</td>
<td>1,975</td>
</tr>
<tr>
<td>Inventories</td>
<td>599</td>
<td>665</td>
</tr>
<tr>
<td>Cash</td>
<td>7,645</td>
<td>5,536</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>1,475</td>
<td>824</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>5,588</td>
<td>1,918</td>
</tr>
<tr>
<td>Total assets</td>
<td>18,282</td>
<td>10,918</td>
</tr>
</tbody>
</table>

**Comments**

- Revenue and grant income up 36%
- >70% gross margin
- Planned expenditure on clinical studies
- R&D Tax Credit £1.1m post year end
- Fund raise £12.7m post year end
- Funding strengthens the business in discussions with corporate partners, extends runway past FDA and prepares for revenue growth
Seeking to be the first company ever to receive an FDA clearance for harvesting cancer cells from blood for analysis

- **Four leading US cancer centres recruiting patients**
- Over 80 subjects out of total of 400 already recruited as at 1 June 2018
- **FDA studies on track for completion in CY18**
- Prospect of FDA clearance in CY19
- **Abbott secured as commercialisation partner for HER-2 FISH analysis**

### ANG-002 STUDY START-UP STATUS (1 June 2018)

<table>
<thead>
<tr>
<th>Tasks</th>
<th>Site 01: MD Anderson</th>
<th>Site 02: USC</th>
<th>Site 03: URMC</th>
<th>Site 04: Northwestern</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution/Investigator Check (FDA restrictions, debarment, etc.)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Received Clinical Protocol and Draft Contract/Budget sent to site</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Site Inspection Completed (e.g. verify bench space for Parsortix instruments and CytoSpin, verify availability of fluorescent microscope and other equipment to be provided by lab, technicians, etc.)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Signed Confidentiality Agreements</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Signed Master Clinical Study Agreement</td>
<td>NA</td>
<td>✓</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td>Signed Clinical Study Agreement and/or Study Specific Exhibit</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Signed Site/Central Laboratory Agreement</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td>Redcap clinical database completed</td>
<td>NA</td>
<td>NA</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td>Instrument Installation and User Training</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>IRB Approval of Protocol and Consent Form(s)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Regulatory Documentation Received (i.e. Signed CV’s, Medical Licenses, Signed Financial Disclosures, GCP Certifications, Informed Consent SOP, Protocol Signature Page, Delegation of Authority Logs, etc.)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Study Binders and Initial supply of Sample Collection and Processing Kits Delivered to Site for SIV</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Study Initiation Visit Scheduled/Completed</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Site Officially Open/Activated to Enroll Patients/Subjects</td>
<td>16-Apr-18</td>
<td>31-May-18</td>
<td>03-Apr-18</td>
<td>23-May-18</td>
</tr>
</tbody>
</table>
Business growth post FDA clearance

- **FDA clearance would be a major validation**
  - generating increased interest from third parties to utilise Parsortix
  - widening the market
  - increasing third party investment in developing Parsortix applications

- **Revenues from clinical applications will be possible** with the potential for rapid growth
  - partnership strategy will increase distribution capability whilst keeping sales costs down

- **Major competitive advantage supporting research use sales**
  - sales to pharma and CROs for drug trials
  - sales to reference laboratories developing laboratory developed tests (LDTs)
  - development of companion diagnostics (CDx)

- **Establishment of additional major partnerships will be facilitated**
  - potential for milestone, royalty and development revenues in addition to sales

- The Parsortix product-based solution married to the partnership approach will provide **significant leverage potential for large scale growth**
Driving commercialisation in a $ multi-billion market

- **Screening for early cancer**: Repeat tests
  - Requires large scale studies over many years
  - Partner with charities and Government
  - Research use sales opportunity

- **Detecting clinically significant cancer**: Repeat tests
  - Triaging for ovarian cancer in pelvic mass surgery ($1bn market)
  - Detecting prostate cancer and assessing aggressiveness (£3bn market)

- **Drug selection**: Repeat tests
  - Collaboration with QIAGEN for ARV7 in prostate cancer (Abiraterone and Enzalutamide)

- **Assessing treatment**: Repeat tests
  - Measurement of metastasis by presence and number of CTCs at different time points
  - (Metastatic breast cancer £1bn market)

- **Remission monitoring**: Repeat tests
  - Periodic assessment against baseline for presence and number of CTCs

**Liquid biopsy market estimates**
- Cowen: $10bn US alone
- Goldman Sachs: $14bn US alone in 2025
- JP Morgan: $22bn Global in 2020
- Piper Jaffray: $28bn US alone
- Roots Analysis: $11bn US and EU in 2030

**qPCR and NGS RNA analysis** to identify suitable drugs in breast cancer

**CTC culturing** and live drug analysis under development

- Actively progressing
- Next area of opportunity post FDA clearance
- Requires partner to progress
Clinical application

Ovarian cancer pelvic mass triage test

US $1 billion p.a. market potential

- **400 patient clinical studies completed**
- **Potential to significantly out-perform current clinical care** in discriminating malignant from benign — up to 95% sensitivity and nearly double specificity of CA125. ROC-AUC 95.1% considered excellent
- **Ziplex worked very well with 60 genes in this study**
- Optimisation in progress to improve performance still further
- **Further studies (12-18 months) to support launch as a clinical assay**
- Opportunities for accelerated commercialisation via commercial partnerships
- **750,000 women p.a. with abnormal pelvic mass in US market alone**

---

**Dr Richard Moore, Director of the Gynecologic Oncology Division, University of Rochester Medical Center\nWilmot Cancer Institute**  “The next generation ANGLE PMT test has the ability to out-perform current clinical practice in accurately discriminating malignant from benign pelvic masses prior to biopsy or surgery. The improved accuracy of the test results in a high level of sensitivity as well as a substantial reduction in false positives.”
Ziplex® high performance multiplex downstream analysis solution

**Ziplex system**
- benchtop laboratory platform designed for routine and focused multiplex analysis of DNA, RNA and protein biomarkers
- sample to answer solution for distributed testing under development

**HyCEAD chemistry**
- enables simultaneous measurement of 100’s of genes while eliminating multiplex PCR constraints
- rapid content creation for new applications: >500 target genes to date

**Consumables**
- Flow-thru TipChip® containing gene or protein expression panels for common pathways or disease processes
- HyCEAD reagents and assay controls

**Software**: embedded software for method creation, data gathering and data analysis

**Patented product solution**
Breast cancer FDA clearance progress

- Analytical studies progressing well
  - precision and reproducibility
  - accuracy and linearity
  - limits of quantification and detection
  - interferents and carryover

- ANG-002 clinical study in progress
  - 200 metastatic breast cancer patients and 200 age appropriate healthy volunteers
  - enrolment over 80 subjects achieved as at 1 June 2018 over a two month period with two centres

- MD Anderson leading primary endpoint analysis to confirm CTCs harvested for analysis

- Secondary endpoints qPCR, FISH (Abbott), RNA-Seq

- 4 leading US cancer centers enrolling
  - University of Texas MD Anderson Cancer Center
  - University of Rochester Wilmot Cancer Center
  - University of Southern California Norris Comprehensive Cancer Center
  - Robert H Lurie Comprehensive Cancer Center Northwestern University

- Studies expected to complete CY18
Clinical application

Non-invasive metastatic breast cancer biopsy

£1 billion p.a. market potential

- CTCs harvested and RNA-Seq analysis successful for 100% of patients (21 patient study)

- **CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 genes to the traditional biopsy of cancer cells from metastatic sites in all cases**

- **Wide range of metastatic sites**
  - skin, pleural effusion (fluid around the lung), pericardial effusion (fluid around the heart), breast, cerebrospinal fluid (fluid found in brain and spine) and bone tissue

- **CTCs provide information on 66 different pathways that may be targeted by new or existing cancer drugs**

**USC Norris Comprehensive Cancer Center**

Julie E. Lang, MD, FACS, Director, USC Breast Cancer Program, Associate Professor of Surgery, Norris Comprehensive Cancer Center, University of Southern California

“Successful validation of our approach in future clinical studies could revolutionize clinical management of metastatic breast cancer and advance the promise of personalized cancer therapies, ultimately positively changing the outcome for patients with metastatic disease.”
Collaboration with Abbott for HER-2 FISH application

- **Abbott is the global leader for FISH testing in solid tissue biopsies**

- Physicians use the FISH HER-2 result to determine whether a patient should receive Herceptin (Trastuzumab)
  - about 1 in 5 breast cancer patients have a positive HER-2 result
  - FISH 2016 market estimate $0.5 billion p.a. CAGR 6.8% (source: Grand View Research)

- **A patient’s HER-2 status can change and there is a need to assess HER-2 status at later points when a tissue biopsy is not feasible**

- ANGLE’s ANG-002 FDA clinical study is assessing the use of Abbott’s PathVysion FISH probes on CTCs harvested from blood

---

**Kathryn B Becker, PhD, Franchise Director Oncology and Companion Diagnostics, Abbott**

“Abbott is pleased to collaborate with ANGLE in this important evaluation of PathVysion in liquid biopsy specimens. The PathVysion HER-2 DNA FISH Probe kit is reliable and accurate in tissue biopsy samples and the Parsortix system may unlock the potential for PathVysion use in a simple blood test.”
Non-invasive prostate biopsy

© ANGLE plc 2018

£3 billion p.a. market potential

Barts Cancer Institute pilot studies
- harvested CTCs in 100% of patients (52 patient study)
- number of mesenchymal CTCs showed good correlation to Gleason score (80 patient study)

Simple blood test ahead of a standard tissue biopsy test to reduce unnecessary tissue biopsies
- detect presence of prostate cancer
- assess aggressiveness of disease
- patient risk stratification – differentiate between active surveillance (indolent) or intervention (aggressive)

Blood cell discovery: cells identified as megakaryocytes linked to patient survival (40 patient study)
- option for worldwide exclusive licence over megakaryocyte IP

Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer Institute
“Parsortix has shown the potential to detect more severe cancer cases where the patient is likely to die sooner thereby providing information which may enable clinicians to provide different treatment for their patients, potentially extending lives of those battling with cancer.”
Prostate cancer aggressiveness – the key question

Kaplan-Meier curve: 40 patient study

- Patients classified as high risk using the Parsortix system 10x more likely to die than those classified as low risk

Source: “The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis” Barts Cancer Institute published by Clinical Cancer Research, June 2017
Co-marketing agreement with leading molecular testing company, QIAGEN

**QIAGEN leading molecular testing company**
- 500,000 customers and $1.3bn revenues
- NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities

**Selected Parsortix after year long evaluation process**
identifying key benefits of Parsortix
1) Epitope-independent: captures all relevant cells
2) Cells harvested intact and alive
3) Highly sensitive: works with almost all patients

**First application AR-V7 in prostate cancer**

Michael Kazinski, QIAGEN’s Senior Director Molecular Preanalytic Technologies
“ANGLE’s Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis. It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The combination will allow scientists and clinical researchers to significantly advance their research.”
Research use - growing body of evidence – becoming the CTC system of choice

🌟 Growing user base (in-house, KOLs, customers and evaluations)
- over 200 Parsortix instruments in active use (30Apr17: 145)
- over 49,000 blood separations performed (30Apr17: 30,000)

🌟 Product based solution drives leveraged R&D model
- access KOL/customer experience, expertise and facilities (patients, downstream analysis such as NGS, etc.)
- R&D funded and developed by customers

🌟 KOLs and customers researching 21 different cancer types
- proven performance with multiple leading translational researchers
- publish evidence of utility and present at conferences - viral marketing
- informs NPD and generates pipeline of new clinical applications
- breakthrough research offers potential to expand IP

🌟 Horizon 2020 EU grant €6.3m with Philips (£0.4m to ANGLE)

🌟 Potential to be first FDA cleared system for harvesting CTCs
- first mover advantage (third in liquid biopsy) and new “Gold Standard”

---

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Cassette</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price²</td>
<td>£40,000</td>
</tr>
<tr>
<td>Cost²</td>
<td>£12,000</td>
</tr>
<tr>
<td>Margin</td>
<td>70%</td>
</tr>
</tbody>
</table>

1. Indicative. High margins allow flexibility in pricing for competitive advantage
2. Includes maintenance, technical support, sales and distribution

---

<table>
<thead>
<tr>
<th>Published evidence (cumulative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30Apr18</td>
</tr>
<tr>
<td>Publications</td>
</tr>
<tr>
<td>Posters²</td>
</tr>
</tbody>
</table>

1. Publicly available only. Additional posters withheld for patent / peer-reviewed publications

---

<table>
<thead>
<tr>
<th>Research use sales £250m p.a. potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer research centres</td>
</tr>
<tr>
<td>Cancer drug trials:</td>
</tr>
<tr>
<td>- 750 addressable Phase II @ £100k / trial</td>
</tr>
<tr>
<td>- 120 addressable Phase III @ £750k / trial</td>
</tr>
</tbody>
</table>
Strengthening a leading position in emerging $ multi-billion liquid biopsy market

- Providing the **Complete Picture** - viable, intact CTCs for DNA, RNA, and protein analysis (not just ctDNA)

- Clinical study in progress to support **first ever FDA clearance** in metastatic breast cancer expected to complete in H2 CY18

- Ovarian cancer application successfully completed 400 patient studies with AUC 95.1% out-performing standard of care and in optimisation

- Ziplex system provides further differentiation for CTC sample to answer in liquid biopsy

- Collaboration agreements with QIAGEN, Abbott and Philips